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SUMMARY
Malignant astrocytomas are infiltrative and incurable brain tumors. Despite profound therapeutic implica-
tions, the identity of the cell (or cells) of origin has not been rigorously determined. We previously reported
mouse models based on conditional inactivation of the human astrocytoma-relevant tumor suppressors
p53, Nf1, and Pten, wherein through somatic loss of heterozygosity, mutant mice develop tumors with
100%penetrance. In the present study,we show that tumor suppressor inactivation in neural stem/progenitor
cells is both necessary and sufficient to induce astrocytoma formation. We demonstrate in vivo that trans-
formed cells and their progeny undergo infiltration and multilineage differentiation during tumorigenesis.
Tumor suppressor heterozygous neural stem/progenitor cultures from presymptomatic mice show aberrant
growth advantage and altered differentiation, thus identifying a pretumorigenic cell population.INTRODUCTION
Gliomasare themostcommonprimarymalignanciesof thecentral
nervous system (CNS). Astrocytomas, which account for the
majority of these tumors, exhibit histologic resemblance to astro-
glial cells. The most malignant form, glioblastoma multiforme
(GBM), is one of the most lethal forms of cancer, with a median
survival of about one year (Maher et al., 2001; Zhu and Parada,
2002). These highly infiltrative tumors are resistant to conventional
radiationandchemotherapy, resulting indismal survivaloutcomes
that, in contrast to some forms of cancer, have improved only
marginally in the past several decades (Stupp et al., 2005).
A variety of mutations have been described in human astrocy-
toma, and these frequently disrupt cell-cycle and apoptosisregulation (INK4A, CDK4, RB, TP53) and growth factor receptor
signaling (EGFR, PDGFR, PTEN) (Furnari et al., 2007). These
genetic lesions have been exploited in mice to generate animal
models that phenocopy the human malignancy and thus allow
for in vivo investigation of tumor development and their use in
translational studies. A number of these mouse models involve
introduction of oncogenic mutations in the germline or specific
cell subpopulations in the brain. These include overexpression
of active forms of Ras, Akt, epidermal growth factor receptor
(EGFR), and platelet-derived growth factor (PDGF) as well as
transforming antigens such as v-src and polyoma middle
T-antigen, often in combination withmutations in tumor suppres-
sors such as Ink4A or Arf (Fomchenko and Holland, 2006). The
first endogenous genetic tumor suppressor mouse model wasSIGNIFICANCE
Identification of the original cell that gives rise to a tumor and whether it is a limited cell type has crucial implications for
understanding cancer development. This knowledge is also requisite for rigorous investigation of tumor initiation mecha-
nisms. Using fully penetrant mouse models, we identify neural stem/progenitor cells as cancer-initiating cells and derive
insight into the behavior of these tumors. We also report malignant astrocytoma mouse models wherein tumor suppressor
inactivation at embryonic, early postnatal, or adult ages induces tumor formation and demonstrates the capacity of tumor
cells to differentiate within the tumor. Our studies on presymptomatic mutant progenitor cultures indicate that the disease
could be disseminating and acquiring growth advantage long before the onset of clinical manifestations.
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Nf1, a Ras GTPase-activating protein (RasGAP) and effector of
receptor tyrosine kinase signaling, and Trp53 (p53). Depending
on genetic background, these mice develop brain tumors with
varying penetrance (Reilly et al., 2000).
Further refinements have been made through cre/lox tech-
nology,whereinmousestrainswithgermlineor somatic heterozy-
gous mutations of the p53, Nf1, and Pten tumor suppressors
develop high-grade astrocytomas with 100% penetrance (Kwon
et al., 2008; Zhu et al., 2005a). TP53 and PTEN mutations are
among the most frequent mutations reported in astrocytomas
(Furnari et al., 2007; Maher et al., 2001). Patients with germline
mutations in NF1, called neurofibromatosis type 1, have
increased susceptibility to astrocytomas (Gutmann et al., 2002),
and recent detailed investigations of this 350 kb gene by the
Cancer Genome Atlas Research Network indicate that along
with PTEN and TP53, somatic NF1 mutations are also prevalent
in sporadic GBMs. In fact, these three genes are among the top
fivemostmutatedgenes inhumanGBMs (McLendonetal., 2008).
Mouse models harboring a heterozygous germline or condi-
tional somatic p53 mutation combined with conditional somatic
Nf1heterozygosity develop low- tohigh-grade (secondary) astro-
cytomas (Zhu et al., 2005a). Tumor formation is further acceler-
ated into high-grade astrocytomas similar to primary GBM by
additional loss of Pten (Kwon et al., 2008). These fully penetrant
endogenous tumor suppressor-based mouse models develop
tumors that are indistinguishable from the human malignancy
based on known histologic and molecular criteria that define
human astrocytomas.
The subventricular zone (SVZ) is an extensive germinal layer
that concentrates neural and glial progenitors on the walls of the
lateral ventricles of adult mammals (Alvarez-Buylla and Lim,
2004). In rodents, SVZ neural stem cells correspond to type B
cells. These primary progenitors give rise to transient amplifying
type C cells that undergo limited mitoses before differentiating
into neuroblasts thatmigrate through the rostralmigratory stream
(RMS) and into the olfactory bulb (OB) (Doetsch et al., 1999).
Neurogenesis also occurs in the subgranular zone (SGZ) of the
dentate gyrus, which produces local neurons that incorporate
into the granular cell layer (GL) (Gage, 2000; Zhao et al., 2008).
In humans, the SVZ and SGZ have both been shown to harbor
neural stem cells (Eriksson et al., 1998; Sanai et al., 2004). Recent
studieshavesuggested theexistenceof additional, thoughminor,
stem/progenitor niches elsewhere in the brain (Gould, 2007).
Historically, astrocytomas have been thought to arise from
differentiated glia that undergo a process of dedifferentiation
(Sanai et al., 2005; Sauvageot et al., 2007). However, whether
mature differentiated astrocytes in their normal parenchymal
environment are capable of initiating tumor formation in vivo
has not been rigorously tested. The recent identification of adult
neural stem cells, immature cells that divide throughout the life-
time of the individual, presents attractive targets for acquisition
of tumor-causing mutations.
In the clinical setting, it is impossible to determine either the
location of tumor origin or the nature of the cell type (or types)
capable of generating these tumors. Similarly, because of astro-
cytoma’s infiltrative nature from the early onset, it is impossible
to determine the in vivo fate of tumor cells. Many theories have
been put forth regarding these issues, including an astrocytic
46 Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc.origin for GBM. Additionally, GBMsmay contain highly heteroge-
neous tumor-derived cells that can differentiate. Despite the
fundamental implications for development of therapies, direct
examination or proof of these ideas remains to be provided.
Physiologically relevant genetic mouse models of high-grade
astrocytomas provide one approach to address these critical
questions. Examination of events preceding unassailable tumor
development in our mouse models suggested that the tumors
arise in the SVZ and possibly within stem/progenitor cells (Zhu
et al., 2005a; Kwon et al., 2008). To directly examine whether
neural stem/progenitors are the source of astrocytomas, we
undertook a two-pronged approach. Using both genetic and
stereotactic injection methods, we demonstrate that in the
context of prevalent mutations and aberrant signaling pathways
found in idiopathic glioma—TP53, NF1, and PTEN—embryonic,
early postnatal, and, importantly, adult neural stem/progenitor
cells can give rise to malignant astrocytomas in vivo, whereas
more mature cell types cannot.
RESULTS
Genetic Tumor Suppressor Targeting of Neural
Stem/Progenitor Cells Induces Astrocytomas
Our previous astrocytomamousemodels relied on heterozygous
deletion of the tumor suppressors Nf1, p53, and/or Pten using
a human GFAP promoter-controlled cre transgenic line
(hGFAP-cre) to drive recombination (Zhuo et al., 2001), followed
by spontaneous loss of heterozygosity (LOH) at these loci (Kwon
et al., 2008; Zhu et al., 2005a). TheGFAP promoter used in these
conditional knockout mice is expressed in both stem cells and
white matter astrocytes. Thus, whether the tumors arose from
the neural stem/progenitors cells could not be determined.
To directly examine whether tumor suppressor depletion in
neural stem/progenitors was sufficient to induce astrocytoma
formation, we targeted neural stem/progenitor cells in vivo using
a transgene that expresses a cre recombinase-modified estrogen
receptor ligand-bindingdomain fusionprotein (cre-ERT2) under the
control of theNestinpromoter/enhancer (Chenet al., 2009). Nestin
is an intermediate filament protein that is widely used to mark
neural stem/progenitor cells but not differentiated astrocytes,
and the second intron enhancer allows for neural precursor-
specific expression in the CNS (Lendahl et al., 1990; Zimmerman
et al., 1994). Tamoxifen administration induces nuclear transfer
of the cre-ERT2 protein in nestin-expressing cells, where it can
mediate loxP-dependent recombination (Feil et al., 1996). In
a Rosa26 b-galactosidase (R26-lacZ) reporter background (Sor-
iano, 1999), neural stem/progenitor cells and all of their progeny
are indelibly marked by lacZ, which can be identified by X-gal
staining (Figures 1A and 1B). Induction at embryonic day 13.5
(E13.5) produced a broad pattern of expression similar to the
hGFAP-cre transgene that was used for the Nf1-p53-Pten condi-
tional astrocytoma mouse models (Kwon et al., 2008; Zhu et al.,
2005a), reflecting expression in embryonic telencephalic progeni-
tors (Figure 1A). Induction at early postnatal stages exhibited
marked and progressively reduced recombination in parenchyma
(Chen et al., 2009), and by adult ages, lacZ staining in the forebrain
andmidbrainalmostexclusively labeled theneural stemcells in the
SVZand its progeny along theRMSandOB, aswell asprogenitors
in the SGZ and their progeny in the dentate gyrus (Figure 1B).
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Cell of Origin of Malignant AstrocytomasFigure 1. Tumor Suppressor Inactivation in Nestin-Expressing Neural Stem/Progenitor Cells Induces High-Grade Astrocytoma Formation
(A and B) Nestin-cre-ERT2 transgenic mice possess cre recombinase activity in the neural stem/progenitor niches.
(A) Representative images of X-gal-stained adult brain sections show that cre activity of Nestin-cre-ERT2;R26-lacZ mice treated with tamoxifen at E13.5 reca-
pitulates that of hGFAP-cre transgenic mice. Scale bar = 2 mm.
(B) Representative images of X-gal-stained brain sections at 6 months postinjection (MPI) reveal that tamoxifen induction at 4 weeks of age mainly restricts cre
activity to neural stem cells and their progeny in the subventricular zone (SVZ), rostral migratory stream (RMS), and olfactory bulb (OB), as well as in the subgra-
nular zone and granule cell layer of the dentate gyrus in the hippocampus (HP). Transgene expression is also found in the cerebellum. No staining is found in the
adult cortex (CTX) or striatum (ST), or in vehicle-treated mouse brains. Scale bar = 2 mm.
(C) Mice with induced tumor suppressor inactivation (Nestin-cre-ERT2;Nf1flox/+;p53flox/flox;Ptenflox/+ or Nestin-cre-ERT2;Nf1flox/flox;p53flox/flox) by tamoxifen
treatment (TMX) have shortened survival compared to vehicle-treated (Veh) mice. Kaplan-Meier survival curves of Nestin-cre-ERT2 mice with tumor suppressor
inactivation induced at either E13.5 or 4 weeks of age showmedian survival durations of 16weeks and 46weeks, respectively. Red arrow indicates timing of adult
injection.
(D) Histologically identifiable high-grade astrocytomas develop in inducible mutant mice. Representative hematoxylin and eosin (H&E)-stained brain sections
reveal formation of brain tumors in Nestin-cre-ERT2 mice with tumor suppressor inactivation induced at either E13.5 or 4 weeks of age. Grade III or IV astrocy-
tomas with characteristic features of nuclear atypia, mitoses (arrowheads), and necrosis (N) are shown. Scale bars = 100 mm.
(E) Tumors express traditional markers of astrocytomas, including Ki67, GFAP, nestin, and Olig2. Scale bar = 100 mm.Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc. 47
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the tumor suppressor floxed alleles (either Nf1flox/+;p53flox/flox;
Ptenflox/+ or Nf1flox/flox;p53flox/flox) and injected pregnant females
with tamoxifen at E13.5 or adult mice at 4 weeks of age. All
tamoxifen-treated (TMX) mutant mice developed high-grade
astrocytomas, while vehicle-treated (Veh) mice did not (Fig-
ure 1C). E13.5 TMX mutant mice developed tumors at a rate
similar to the previously reported hGFAP-cre;Nf1flox/+;p53-/flox;
Ptenflox/+ mouse strain (Kwon et al., 2008), with amedian survival
of around 16 weeks. Mutant mice injected with tamoxifen at
4 weeks of age developed tumors with a median survival of
around 46 weeks. Hematoxylin and eosin (H&E) staining of these
tumors showed the classical features of diffusely infiltrating
astrocytomas, including nuclear atypia and prominent mitoses
as well as necrosis (Figure 1D). Both E13.5- and adult-treated
mutant mice developed tumors diagnosed as grade III or IV
(GBM) astrocytomas based on the World Health Organization
classification system (see Figure S1A and Table S1 available on-
line). These tumors had large numbers of Ki67+ cells, indicating
robust proliferation, and were immunoreactive for GFAP, nestin,
and Olig2 (Figure 1E), acknowledged markers of human astro-
cytic tumors (Furnari et al., 2007). Consistent with activation of
the Ras and Akt signaling pathways by loss of Nf1 and Pten,
respectively, some tumor regions showed robust pERK and
pAKT expression (Figure S1B). We further confirmed LOH of
Figure 2. Cancer-Initiating Cells Exhibit
Infiltration and Differentiation During Tumor
Development
(A) b-galactosidase (b-gal)-positive mutant cells
infiltrate into adjacent brain structures, away from
their normal neural stem/progenitor niches. A
representative X-gal-stained brain tumor
section from aNestin-cre-ERT2;Nf1flox/+;p53flox/flox;
Ptenflox/+;R26-lacZ mouse 8 months after tumor
suppressor inactivation shows tumor cells found
outside of their original locations in the SVZ/SGZ
niches (compared to Figure 1B). b-gal-positive
tumor cells, shown here expressing GFAP, nestin,
and PDGFRa, are found elsewhere in the forebrain,
such as the cortex and striatum.
(B) Marked astrocytoma cells expressing multiline-
age markers are found in the tumor bulk. b-gal-
positive tumor cells in inducible mutant mice,
shown here in the thalamus, express markers of
neuronal (Tuj1) and glial (S100b and APC) differen-
tiation. Toto-3 was used to mark cell nuclei.
the tumor suppressor alleles in tumors
by immunostaining and genotyping (Fig-
ure S2). Thus, cre-mediated somatic
mutation of Nf1, p53, and Pten restricted
to the neural/stem progenitor compart-
ment is sufficient to replicate the high-
grade astrocytoma phenotype previously
observed using combinations of germline
and somaticmutations and a less specific
hGFAP-cre driver (Kwon et al., 2008; Zhu
et al., 2005a). Furthermore, loss of Nf1,
p53, and/orPtenwaspresent in all tumors
and is therefore apparently required for high-grade tumor
induction (Kwon et al., 2008).
Cancer-Initiating Cells Undergo Infiltration
and Spontaneous Differentiation
The presence of the R26-lacZ reporter in the context of the
floxed tumor suppressors allows for lineage tracing of cells as
they undergo tumorigenic transformation. While normal neural
stem cells and their progeny are principally restricted to the
SVZ-RMS-OB and SGZ-GL (Figure 1B), tumors arising from
inducible mutant mice were found in adjacent brain regions,
including the cortex and striatum, as shown by X-gal staining
(Figure 2A). The cre transgene is expressed in cerebellum, but
only one tumor was found in cerebellum, and it resembled astro-
cytoma rather than medulloblastoma, which is the idiotypic
tumor of this brain region. The b-galactosidase-positive tumor
cells costained with the astrocytoma markers GFAP, nestin,
and platelet-derived growth factor receptor a (PDGFRa; Fig-
ure 2A). Thus, mutant stem cells or their progeny migrate away
from their normal niches and invade the parenchyma during
tumor development.
Astrocytomas are heterogeneous tumors, with varying cellular
morphologies and presence of immature andmaturemarkers for
all neural lineages. Upon examination of the tumor bulk, we
found a variety of b-galactosidase-positive cells coexpressing
48 Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc.
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marker Tuj1 and the glial markers S100b and adenomatous
polyposis coli (APC), as shown in a thalamic tumor in Figure 2B.
These immunoreactive tumor cells morphologically resembled
mature neurons, astrocytes, and myelin-ensheathing oligoden-
drocytes. In contrast to normal CNS cells, which show abundant
PTEN expression (Kwon et al., 2008), thesemarker-positive cells
were PTEN negative (Figure S2C), confirming that these ‘‘differ-
entiated’’ cells were indeed cancer cells. These data provide
formal evidence that tumor cells have the stem/progenitor
capacity to exit the cell cycle and at least partially differentiate
in situ. This may account for the heterogeneity of tumor cell types
that is classically associated with high-grade astrocytomas.
Stereotactic Viral cre-Mediated Targeting of the SVZ
Induces Astrocytoma Formation
As an independent approach for targeting cre recombinase to
the SVZ neurogenic niche, we adopted a stereotactic injection
method. Numerous studies have used stereotactic targeting to
study the function, lineage, and identity of neural stem cells by
delivery of dyes, growth factors, or viral particles directly into
the SVZ (Doetsch et al., 1999; Merkle et al., 2004, 2007; Yoon
et al., 1996). Injection of cre recombinase-expressing adenovirus
alone into the SVZ of R26-lacZ reporter mice results in labeled
neural stem cells in the SVZ and their progeny as they travel
through the RMS and into the OB (Figure 3A, right panels). In
contrast, cre adenovirus injection into nonneurogenic regions
such as the cortex or striatum causes only localized labeling in
the area of the injection and no labeling in the RMS or OB
(Figure 3A, left panels). In both cases, restricted staining can
also be found along the needle tract.
We injected cre adenovirus into the SVZ of three strains of
tumor suppressor floxed mice (Nf1flox/flox;p53flox/flox, Nf1flox/flox;
p53flox/, and Nf1flox/+;p53flox/flox;Ptenflox/+) either at postnatal
day 1–2 or adult ages (4–8 weeks). We found that viral cre-medi-
ated tumor suppressor inactivation in the SVZ at both early post-
natal and adult ages induced astrocytoma formation (Figure 3;
Table 1). Injectedmutant mice developed brain tumors classified
as grade III or IV astrocytomas starting at 6 months postinjection
(Figure S3A; Table S2). These tumors exhibited the histopatho-
logic hallmarks of high-grade astrocytomas, including diffuse
infiltration, nuclear atypia, mitoses, microvascular proliferation,
and necrosis (Figure 3B), and were indistinguishable from those
of our previous studies (Kwon et al., 2008; Zhu et al., 2005a).
The tumors were immunoreactive for Ki67, GFAP, and nestin
(Figure 3C) as well as Olig2, pERK, and pAKT (Figure S3B). We
further confirmed that the tumors underwent cre recombination
by b-galactosidase immunostaining (Figure 3C). An internal
Figure 3. Stereotactic Viral cre-Mediated
Targeting of the SVZ Induces Astrocytoma
Formation, Whereas Targeting of Non-
neurogenic Regions Does Not
(A) Schema of the viral cre injection experiments
and representative X-gal staining images. Right:
cre adenovirus targeting of the SVZ in R26-lacZ
reporter mice marks neural stem/progenitors and
their progeny in the RMS (arrowheads) and OB.
Left: cre virus injection into nonneurogenic regions
such as the striatum causes localized labeling at
the site of injection, but no labeling at the RMS
or OB. Scale bar = 2 mm.
(B) SVZ-targeted mutant mice develop histologi-
cally identifiable high-grade astrocytomas. Cre
adenovirus was stereotactically injected into the
SVZ of tumor suppressor floxed mice (Nf1flox/flox;
p53flox/flox, Nf1flox/flox;p53flox/, or Nf1flox/+;
p53flox/flox;Ptenflox/+). Analysis of injected mouse
brains by H&E staining shows infiltrative tumor
cells in SVZ-injected mutant mice (cre/SVZ),
whereas mice injected in other nonneurogenic
brain regions (cre/other) do not develop tumors.
Tumors from SVZ-targeted mutant mice show
classic histopathologic characteristics of high-
grade astrocytomas, including tumor (T) invasion
into normal (nontumor, NT) regions, nuclear atypia
and mitosis (arrowhead), microvascular prolifera-
tion (MP), and necrosis (N). Scale bars = 200 mm.
(C) Tumors from SVZ-targeted tumor suppressor
floxed mice with R26-lacZ reporter show charac-
teristic expression of the astrocytoma-associated
markers Ki67, GFAP, and nestin. Scale bars =
200 mm.
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tion that intended injections into the SVZ resulted in lacZ lineage
tracing of the SVZ-RMS-OB axis. We observed that only
successful SVZ-RMS-OB targeted injections, as evidenced by
X-gal staining in the tumor bulk, SVZ, and the olfactory bulb
(Figure 4A) as well as b-galactosidase immunohistochemistry
(data not shown), generated astrocytomas. We also confirmed
loss of tumor suppressor alleles in tumors by PCR genotyping
(Figure 4A).
Similar to the nestin-inducible mutant mice, tumors were
found throughout most of the brain parenchyma (Figure 4A).
Early postnatal-injected mutant mice seemed to develop more
extensive tumors compared to adult-injected mutant mice,
which developed more restricted, albeit still invasive, high-grade
astrocytomas. Clear evidence of migration is shown by the pres-
ence of tumors away from the SVZ, such as in the cortex, hippo-
campus, and thalamus. In both cases, we found intense X-gal
staining of the tumor regions, as well as in the SVZ-RMS-OB
(Figure 4A).
As described in the tamoxifen-inducible tumors, b-galactosi-
dase-positive tumor cells hadmorphological features of differen-
tiated CNS cells and expressed mature markers, including the
astrocytic marker GFAP, the oligodendrocytic marker myelin
basic protein (MBP), and the neuronal marker NeuN (Figure 4C).
As an independent method of confirming that these marker-
positive cells were indeed tumor cells, we stained these tumors
for PTEN, which is frequently suppressed in high-grade astrocy-
tomas. We found that a number of these ‘‘differentiated’’ cells
were PTEN negative (Figure 4C). We also found a rare population
of b-galactosidase-positive tumor cells near the cortex that
expressed calbindin (Figure 4C), which is normally expressed
by a subset of OB neurons produced by the SVZ neural stem/
progenitor cells (Merkle et al., 2007). These data demonstrate
that cancer-initiating cells or their progeny have the capacity to
migrate throughout the parenchyma, seed tumors, and give rise
to differentiated cell types during tumor development.
Table 1. Astrocytoma Formation in Tumor Suppressor Floxed
Mice by Stereotactic Viral cre Injection
Age at
Injection
Experiment:
Virus/Target Area
Tumor Incidence/Mice
Targeted
Early postnatal cre/SVZ 10/10
cre/other regions 1/12
controlsa 0/8
Adult cre/SVZ 12/12
cre/other regionsb 0/20
controlsa 0/9
Early postnatal (postnatal day 1–2) or adult (4- to 8-week old) mutant mice
were injected with cre adenovirus targeted to the subventricular zone
(SVZ) or nonneurogenic brain regions such as the cortex and striatum.
All adult SVZ-targeted mice developed tumors, whereas mice targeted
in the nonneurogenic regions did not.
a Controls included Ad-GFP injected into the SVZ or cortex/striatum of
tumor suppressor mutant mice and Ad-Cre injected into R26-lacZ mice
alone.
bNine out of 20 injections were intended SVZ injections that missed and
did not result in LacZ+ SVZ-RMS-OB; 11 of 20 injections intentionally
targeted cortex or striatum.50 Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc.Viral cre-Mediated Targeting of Adult Nonneurogenic
Brain Regions Does Not Induce Tumor Formation
The above results demonstrate that progenitor cells in the SVZ
have the capacity to give rise to astrocytomas. However, these
studies do not rule out the possibility that additional parenchymal
cells might also harbor this capacity, or that tumors might arise
from the few cells that are infected with the cre adenovirus along
the injection track. Previous studies using other experimental
systems,which involved in vitromanipulation or oncogenic trans-
formation, have suggested that mature astrocytes can also give
rise to gliomas (Bachoo et al., 2002; Dai et al., 2001; Uhrbom
et al., 2002). In order to target tumor suppressor inactivation to
cells outside the SVZ including astrocytes in vivo, we stereotacti-
cally delivered cre adenovirus into the cortex or striatum of 4- to
8-week-old tumor suppressor floxed adult mice injected in
parallel with the previously described SVZ injections. In contrast
to the successful SVZ injections, where 100% of the mice
developed tumors, none of the animals injected in the cortex or
striatum showed evidence of tumor formation (Figure 3B; Table
1), despite clear evidence of successful cre adenovirus infection
as demonstrated by X-gal staining and PCR genotyping (Fig-
ure 4B) or b-galactosidase immunohistochemistry (Figure S4).
H&E staining showed disorganization of the cortical or striatal
architecture in the injection site (Figure 3B),while immunostaining
showed the presence of GFAP-positive but Ki67-negative cells
(Figure S4), which is indicative of fibrosis and astrogliosis (Zhu
et al., 2005b). Cells near the injection site likewise stainedpositive
for nestin and vimentin (Figure S4), consistentwith reactive astro-
cytosis (Correa-Cerro and Mandell, 2007; Sofroniew, 2005),
phenotypes that are similar to GFP adenovirus-injected control
brains (data not shown).
Non-SVZ regions were also targeted at early postnatal ages,
and the majority of these mice did not develop gliomas (Table
1). However, we did find 1 out of 12 cases where a non-SVZ-
targeted neonatal floxed mouse developed tumors 7 months
postinjection. This is consistent with prior reports of oncogenic
transformation of early postnatal brain cells. The rarity of tumor
induction in non-SVZ-injected mutant mice is consistent with
the rare targeting of neural progenitor cells in the cortex or stria-
tum that still exist at early postnatal ages (Seaberg et al., 2005)
or, alternatively, the rare targeting of radial glia that project into
the parenchyma and are the progenitors of SVZ adult stem cells
(Merkle et al., 2007). Overall, these data indicate that while tumor
suppressor targeting of SVZ neural stem/progenitor cells readily
induces high-grade astrocytoma formation, more differentiated
cell types are less susceptible to malignant transformation by
the tumor suppressor mutations assessed in this study.
Pretumorigenic Neural Stem/Progenitor Cells in the SVZ
The above studies demonstrate that neural stem/progenitor cells
can spontaneously give rise to malignant astrocytomas in our
tumor suppressor mouse models. This allows us to follow these
cells as they evolve from normal to transformed cells, as well as
to investigate the molecular events involved in tumor initiation.
Hence, we went back to our original tumor mouse models, which
we have previously shown to exhibit hyperplastic and migration
defects in the SVZ at early stages in vivo (Kwon et al., 2008; Zhu
et al., 2005a). We examined the properties of mutant SVZ cells
as neurospheres, which is the classical assay for studying neural
Cancer Cell
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(A) Left: representative X-gal-stained brain sections from mutant mice targeted with cre adenovirus into the SVZ at early postnatal and adult ages show massive
tumor formation, extensive infiltration andmigration of tumor cells within the brain parenchyma, and labeling of the SVZ-RMS-OB axis. Right: LacZ-positive tumor
(T) and lacZ-negative nontumor (NT) regions were dissected for PCR genotyping, which showed increased recombination of tumor suppressors—in this case, of
floxed Nf1 alleles in tumors. G, tail genomic DNA; F, floxed; D, recombined; +, wild-type (WT) allele.
(B) Left: X-gal-stained brain sections from mice targeted in nonneurogenic regions such as striatum show localized staining at the site of injection and along the
needle tract, but no tumor formation. Right: PCR genotyping of lacZ-positive (lacZ+) and lacZ-negative (lacZ) regions confirms successful recombination of
floxed alleles in lacZ+ samples. Scale bar = 2 mm.
(C) Tumor cells from virus-injected mutant brains exhibit multilineage differentiation. Representative immunostaining images of high-grade astrocytomas from
SVZ-targeted tumor suppressor floxed mice with R26-lacZ reporter injected at early postnatal and adult ages show expression of mature differentiation markers
in a subset of b-gal-positive tumor cells, including GFAP for astrocytes, myelin basic protein (MBP) for oligodendrocytes, and NeuN for neurons. The majority of
marker-positive cells within the tumor bulk (in this case, NeuN-positive cells) were also PTEN negative. A small number of b-gal-positive tumor cells near the
cortex were positive for calbindin, a marker of a subset of differentiated OB neurons derived from the SVZ neural stem/progenitor cells. The insets show a
b-gal/calbindin double-positive cell. Scale bar = 200 mm; inset scale bars = 10 mm.stem/progenitor behavior in vitro (Reynolds and Weiss, 1992).
Interestingly, we found that cultured SVZ neurospheres from
tumor-prone mutant mice (Mut3: hGFAP-cre;Nf1flox/+;p53/+ or
Mut4: hGFAP-cre;Nf1flox/+;p53/+;Ptenflox/+) at young agesprior to
any histologic evidence of hyperplasia exhibited abnormal growth
properties (Figure 5). Comparedwithwild-type controls, heterozy-
gous mutant SVZ neurospheres displayed increased proliferation
as shown by increased neurosphere diameter (Figure 5A) and
bromodeoxyuridine (BrdU) incorporation (Figure 5B), as well as
decreased apoptosis as shown by annexin V staining (Figure 5C).
These cells likewise exhibited abnormal stem cell properties,
including increased self-renewal capacity (Figure 5D), and altered
differentiation potential with decreased astrocytic differentiation
compared to normal cells (Figure 5E; Figure S5). To determine
whether SVZ cells underwent LOH in the youngmicemonths priorto tumor appearance, we performed PCR genotyping of the
tumor suppressor alleles in the abnormal neurosphere cultures.
We noted the presence of wild-type alleles for all tumor suppres-
sors, indicating retention of heterozygosity (Figure 5F). These
data indicate that in the absence of gross morphologic abnormal-
ities, heterozygous tumor suppressor-deficient stem/progenitor
cells already display abnormal growth and differentiation proper-
ties—processes that may serve as a prelude to tumor formation.
DISCUSSION
Neural Stem/Progenitor Cells
as Astrocytoma-Initiating Cells
In this report, we describe the spatial and temporal restriction of
in vivogene targeting to theneurogenicnichesof thebrain throughCancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc. 51
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Cell of Origin of Malignant AstrocytomasFigure 5. Pretumorigenic SVZ Neural Stem/Progenitor Cells Exhibit Growth Advantage and Altered Differentiation
(A) SVZ neurospheres from presymptomatic mutant mice exhibit hypertrophy. SVZ cells of 4-week-old mice were cultured as neurospheres. As shown in repre-
sentative images, Nf1/p53-deficient (Mut3: hGFAP-cre;Nf1flox/+;p53/+) or Nf1/p53/Pten-deficient (Mut4: hGFAP-cre;Nf1flox/+;p53/+;Ptenflox/+) neurospheres
were larger than those from WT neurospheres. Scale bar = 200 mm.
(B) Neurosphere proliferation was measured by 2 hr of bromodeoxyuridine (BrdU) pulsing in day 3 cultures and subsequent fluorescence-activated cell sorting
(FACS) analysis. A significantly higher percentage of Mut3 and Mut4 cells were in S phase compared to WT cells (p < 0.05).
(C) Neurosphere cell death was measured by annexin V labeling and subsequent FACS analysis. Mut3 or Mut4 cells underwent significantly reduced cell death
compared to WT cells. 7-aminoactinomycin (7-AAD) is a vital dye.
(D) SVZ neurospheres from presymptomatic mutant mice exhibit increased self-renewal potential compared to WT as shown by methylcellulose assay
(**p < 0.005).
(E) Quantification of differentiated cells reveals significant increase in Tuj1- or nestin-positive cells and significant decrease in GFAP-positive cells in Mut3 and
Mut4 cultures compared to those of WT control (*p < 0.05, **p < 0.005). All error bars in (A)–(E) are ± standard error of the mean (SEM).
(F) Neurosphere cultures from presymptomatic mutant mice exhibit retention of heterozygosity of tumor suppressor genes. Genomic DNA from the ear (E) or
neurospheres (N) of 4-week-old Mut3 and Mut4 mice was subjected to semiquantitative PCR genotyping. Representative data for cre, Nf1, p53, and Pten status
indicate retention of WT alleles in all Mut3 and Mut4 neurospheres.the use of a tamoxifen-inducibleNestin-cre-ERT2 transgene or by
stereotactic viral-mediated cre recombinase delivery to the SVZ.
The results were striking in that all adult mice subjected to SVZ
targeting developed astrocytomas, thus establishing that muta-
tion of these astrocytoma-relevant tumor suppressors in the
neurogenic compartment in vivo is sufficient to induce tumor
formation. Importantly, all viral injections into the SVZ were vali-
dated postmortem by lacZ staining to verify effective labeling of
the RMS and OB, normal destination sites for progeny derived
from the SVZ. In contrast, viral targeting of adult parenchyma
where the vast majority of cells were differentiated did not yield52 Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc.tumors but instead local astrogliosis and localized lacZ staining,
despite demonstration of recombination in glial cells. The induc-
ible tumor model, on the other hand, showed that specifically
targeting nestin-expressing neural stem and progenitor cells
induces tumor formation. These data strongly support the idea
that mutations in the stem/progenitor compartment account for
the majority of these tumors and identify neural stem/progenitor
cells as cancer-initiating cells in our fully penetrant astrocytoma
mouse models. Furthermore, astrocytoma induction occurs effi-
ciently in embryonic, early postnatal, and adult mice dependent
on stem/progenitor cell targeting of the tumor suppressors.
Cancer Cell
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selected to ensure adequate incubation of all manipulated cells,
whether tumor suppressor-bearing or control. We ended the
studies when specific cohorts exhibited morbidity that in all
cases was verified to be the consequence of advanced astrocy-
toma. Therefore, we did not assess the natural history of tumor
development or the genetic signature of the tumors since the
present models are predicated on our previously extensively
characterized tumor suppressor-based mouse models (Kwon
et al., 2008; Zhu et al., 2005a). Moreover, we cannot rigorously
distinguish between quiescent stem cells or actively dividing
progenitor cells as the cells where LOH originates in our mouse
models. Since the tumors arise months after targeting and, in the
normal course of events, transient amplifying cells reach the OB
and differentiate within two weeks (Petreanu and Alvarez-Buylla,
2002), we favor the hypothesis that the tumorigenic state preex-
ists in the stem cell population but becomes phenotypically
manifest once the cells enter the transient amplifying state.
Experimental investigation of these distinctions will require
more refined cell-type-specific promoters to drive cre-mediated
recombination. It also remains to be determined whether the
differential susceptibility of neural stem cells and astrocytes to
transformation is dependent on local microenvironment.
Cancer Stem Cells in Malignant Astrocytomas
The concept that some or many forms of cancer may be
comprised of a subset of tumor-propagating cells and another
subset of cells that cannot propagate the tumor has recently
received increasing attention (Reya et al., 2001). Dirks and
colleagues initially showed that human GBM xenografts into
immunodeficient mice have such an identifiable subset of
cancer-propagating cells or ‘‘cancer stem cells’’ (Singh et al.,
2004). Cancer stem cells are thus technically defined in terms of
their in vivo capacity for tumor initiation in serial transplantations
and rely on retrospective isolation of these self-renewing cells
(Dalerbaet al., 2007). It is logical then to suggest that thesecancer
stem cells have characteristics in common with stem cells, but
whether normal stem cells are the cells of origin of these tumors
remained to be experimentally established. Our data indicate
thatnormalneural stem/progenitor cells arecancer-initiatingcells
and can readily give rise to high-grade astrocytomas.
Tumorigenic Stem/Progenitors Migrate
and Differentiate Abnormally In Vivo
Astrocytomas are notorious for their infiltrative capacity, a prop-
erty that clinically confounds complete surgical resection. We
show here that in contrast to normal adult neural stem cells
that are strictly confined to the SVZ or SGZ, tumors arising from
tumor suppressor-deficient neural stem cells or their progeny are
not restricted to these niches and actually migrate away from
their normal locations, thus accounting for the presence of
tumors elsewhere in the forebrain, including the cortex, striatum,
hippocampus, and thalamus. This can also explain the presence
of tumors in regions where the hGFAP-cre transgene is not
expressed in conditional mutant mouse models (Kwon et al.,
2008; Zhu et al., 2005a). Another distinct feature of human astro-
cytomas is the heterogeneity of cell types within these tumors.
Because of their infiltrative nature, one interpretation is that
‘‘diverse’’ nontumor cells are present and surrounded by tumorcells. This may be the case to some degree, as genotyping of
primary tumor tissue yields a faint wild-type or nonrecombined
band (Figure 4A and data not shown), and the majority of cells
expressing mature, differentiated markers are b-galactosidase
negative (Figure 2B; Figure 4C), suggesting that normal cells
were trapped within the tumor bulk. An additional alternative is
that the tumor itself has a heterogeneous component of tumor-
derived cells. This alternative has been indirectly supported
by several lines of evidence, including in vitro differentiation
and xenografting into immunodeficient mice. However, direct
demonstration that the original tumor is heterogeneous in situ
has been lacking. The power of mouse genetics permitted neural
stem/progenitor compartment-specific tumor suppressor inacti-
vation in the context of a cre-dependent lacZ reporter transgene.
Thus, through morphologic assessment of lacZ-positive and
PTEN-negative tumor cells in conjunction with labeling with
lineage-specific markers, we found that a subset of tumor-
derived cells have properties of astrocytes, oligodendrocytes,
and neurons. We even found a rare subset of lacZ-positive
tumors cells that express calbindin, which is normally expressed
by a subset of OB neurons produced by the SVZ neural stem/
progenitors, suggesting that the differentiation capacity of these
cancer-initiating stem/progenitor cells is retained during tumor
development.
The degree of differentiation is variable among individual tumor
cells and between tumors from different individuals. However,
since these ‘‘mature’’ cells may represent a less aggressive
population of tumor cells, this observation suggests that differen-
tiation therapy may provide a plausible approach to arresting
tumor growth while avoiding killing ‘‘bystander’’ normal cells. In
sum, the clinically relevant migration and differentiation capacity
of astrocytomas fits well with a neural stem/progenitor cell origin
uncovered here.
Cell of Origin in Mouse and Human Gliomas
Other astrocytoma mouse models have used combinations of
oncogenic overexpression and/or tumor suppressor inactivation
to induce tumor formation. Several reports have shown thatNes-
tin promoter-driven oncogenesis at early postnatal ages can give
rise to astrocytomas, whereas GFAP promoter-driven oncogen-
esis has reduced penetrance depending on the initiating muta-
tions (Holland et al., 2000; Uhrbom et al., 2002). The tumor cell
of origin in these previous studies was inferred but not directly
examined. Ex vivo expansion of cultured neural stem cells or
neonatal astrocytes followed by transplantation into immunode-
ficient mice also gives rise to astrocytomas (Bachoo et al., 2002;
Dai et al., 2001). Thus, to date, cells targeted for transformation
have been derived from either embryonic or early postnatal brain
cells. Moreover, in vitro manipulation to establish tumorigenicity
is likewise problematic because it is well established that cell
culture significantly alters the normal biological behavior of cells.
Studies using oncogenic mutations may also provide supraphy-
siologic levels of activated oncogenes. In light of the present
studies, we suggest that these mouse models may be targeting
embryonic precursors present in neonatal brains, with the
distinction that our models equally target adult stem/progenitor
cells and inducehigh-gradeastrocytomaswith tumor suppressor
inactivation. On the other hand, theCancerGenomeAtlas project
has described EGFR receptor mutations as mutually exclusiveCancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc. 53
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Cell of Origin of Malignant Astrocytomasfrom NF1 mutations in gliomas. Thus, it is possible that other
mutations in neural stem/progenitors can likewise give rise to
gliomas, or that gliomas with differing genetic signatures may
originate from different cell subtypes. The finding that the SVZ
contains a diverse set of neural stem cells that can give rise to
specific progenitor subtypes (Merkle et al., 2007) provides
some clues.Whether these heterogeneous stem cell populations
are susceptible to the same mutations or give rise to different
tumor subtypes also remains to be examined. The experimental
approaches described herein will be useful in determining the
cell of origin of other models using GBM signature mutations or
pathways.
Haploinsufficiency and Tumor Initiation
Themechanisms involved in tumor initiation remain poorly under-
stood, and identification of the cell of origin allows us to follow
normal SVZ cells as they undergo transformation and full-blown
tumorigenesis. We were surprised by the finding that in culture,
pretumorigenic neurosphere-forming cells from the SVZ already
show growth advantage and apoptotic resistance while retaining
heterozygosity. It is also surprising that at these early stages, the
differentiation capacity of these mutant cells is altered, suggest-
ing that the differentiation state of these immature cells is tightly
coupled to self-renewal processes. This underscores the impor-
tance of the Nf1, p53, and Pten tumor suppressor pathways in
regulating normal neural stem cell proliferation and self-renewal.
It also has implications for therapeutic approaches, should the
physiological relevance of our models continue to be validated.
These data imply that there remains a persistent and primed
source of pretumorigenic cells in the neurogenic niche that will
require further investigation and therapeutic targeting.
EXPERIMENTAL PROCEDURES
Mice
All mouse experiments were approved by and performed according to the
guidelines of the Institutional Animal Care and Use Committee of the University
of Texas Southwestern Medical Center at Dallas. Mice with conditional Nf1,
p53, and/orPten alleleswith theR26-lacZ reporter weremaintained on amixed
129SvJ/C57BL/6/B6CBA background (Kwon et al., 2008). Mice harboring the
floxed Nf1 and p53 alleles in ciswere generated by crossing the Nf1flox/+ strain
to the p53flox/+ strain to generate Nf1flox/+;p53flox/+ trans mice that were then
crossed to wild-type mice. Generation and maintenance of Mut3 and Mut4
mice as well as genotyping for the flox, wild-type, and recombinant alleles
were as described previously (Kwon et al., 2008; Zhu et al., 2005a).
Tamoxifen Induction
Tumor suppressor floxedmice containing theNestin-cre-ERT2 transgene were
injected intraperitoneally with vehicle (9:1 sunflower oil:ethanol mixture)
(Sigma) or tamoxifen (Sigma) at aworkingconcentration of 6.7mg/ml. Pregnant
motherswere injectedwith 1mg tamoxifen at E13.5, whereas 4-week-oldmice
were injected with 83.8 mg/kg tamoxifen twice a day for 5 consecutive days
(Chen et al., 2009).
Adenovirus Injection
Tumor suppressor floxed mice at 4–8 weeks of age or postnatal day 1–2 were
injected with cre- or GFP-expressing adenovirus as described previously
(Doetsch et al., 1999; Merkle et al., 2004), with some modifications. Two
hundred nanoliters of adenovirus (Ad-Cre, 2.0 3 1012 plaque-forming units
[pfu]/ml, University of Iowa Vector Core; Ad-GFP, 1.0 3 1011 pfu/ml) was
injected using a World Precision nanoinjector apparatus, according to the
following coordinates (in mm anterior, lateral, and dorsal to the bregma): SVZ
(0, 1.4, 1.6; 0.5, 1.1, 1.7; and 1, 1, 2.3); cortex (0, 3.5, 1.0); and striatum54 Cancer Cell 15, 45–56, January 6, 2009 ª2009 Elsevier Inc.(0, 1.4, 2.6). For early postnatal injections, postnatal day 1 or 2 pups were in-
jected with 40 nl of Ad-Cre or Ad-GFP as described previously (Merkle et al.,
2004), with some modifications. The following coordinates (in mm anterior,
lateral, and dorsal to the bregma) for a range of neonate weights were used:
1.4–1.5 g (1.5, 2.6, 1.4); 1.5–1.7 g (1.6, 2.7, 1.4); 1.7–1.9 g (1.7, 2.9, 1.5); and
>1.9 g (1.7, 2.9, 1.7). All virus- and tamoxifen-injected mice were followed for
development of neurologic abnormalities and harvested for histologic analysis.
Histology and Tumor Analysis
Mice were perfused and fixed with 4% paraformaldehyde. Five micrometer
sections were cut, and every fifth slide was stained with H&E. Brain sections
were independently examined by S.A.L. and J.C. as well as D.K.B., a certified
neuropathologist, and tumor diagnosis was determined based on World
Health Organization criteria (Kleihues et al., 2002). Brains used for X-gal stain-
ing were postfixed in 2% PFA overnight. Half brains or 50 mm vibratome
sections were stained in X-gal solution, and sections were counterstained
with nuclear fast red as described previously (Luikart et al., 2005). In some
cases, half brains stained with X-gal were subsequently processed and used
for immunohistochemistry. For PCR genotyping, DNA extraction and PCR
were performed using tumor and nontumor tissues as described previously
(Kwon et al., 2008).
Immunohistochemistry
Paraffin sections were deparaffinized, rehydrated, and subjected to citrate-
based antigen retrieval. Primary antibodies were used against GFAP (DAKO,
1:1000; BD Biosciences, 1:200), Ki67 (Novocastra, 1:1000), nestin (BD Biosci-
ences, 1:100), Olig2 (Chemicon, 1:1000), b-gal (ICN, 1:1000), NeuN (Chemicon,
1:500), MBP (Sternberger, 1:200), calbindin (Swant, 1:1000), vimentin (Zymed,
1:200), S100b (Sigma, 1:200), pERK (Cell Signaling, 1:400), pAKT (Cell
Signaling, 1:100), PTEN (Cell Signaling, 1:100), and PDGFRa (Spring, 1:50).
We used both immunofluorescence staining with Cy2, Cy3, or Cy5 (Jackson
Labs, 1:400) and biotin-streptavidin Alexa Fluor-conjugated secondary anti-
bodies (Molecular Probes, 1:1000), as well as horseradish peroxidase-based
Vectastain ABC Kit (Vector Laboratories). Sections were examined using
optical, fluorescence, and confocal microscopy (Olympus and Zeiss).
Neurosphere Culture and Assays
Neurosphere cultures were established and maintained as described previ-
ously (Kwonet al., 2008). Tomeasure neurosphere size,we seededdissociated
cells into 24-well plates and acquired all neurosphere images after 7 days of
incubation. We measured neurosphere diameter using MetaMorph software
(Universal Imaging Corporation). Proliferation and apoptosis in neurosphere
cultures were quantified by flow cytometry using BrdU and annexin V analysis
kits (BD Biosciences). Self-renewal assay was performed by plating dissoci-
ated cells with methylcellulose-containing media (final concentration 0.8%,
Sigma) as described previously (Gritti et al., 1999). For differentiation, we
seeded dissociated cells in eight-chamber slides coated with Matrigel (BD
Biosciences, 1:20) and cultured in NeuroCult with differentiation medium
(StemCell Technologies). Quantification was performed in at least n = 3
samples from each genotype, and Student’s t test was used for statistical
analysis.
SUPPLEMENTAL DATA
The Supplemental Data include five figures and two tables and can be
found with this article online at http://www.cancercell.org/supplemental/
S1535-6108(08)00409-1.
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